Pharmacists'Intervention and Analysis of Rivaroxaban Anticoagulant Therapy Prescriptions for Patients with Non-valvular Atrial Fibrillation
10.3870/j.issn.1004-0781.2025.11.014
- VernacularTitle:药师对非瓣膜性心房颤动患者利伐沙班抗凝治疗处方的干预和分析
- Author:
Puqing LIU
1
;
Yu WANG
;
Jingwen CHEN
;
Zhangxuan SHOU
Author Information
1. 浙江中医药大学附属第二医院药剂科,杭州 310005
- Publication Type:Journal Article
- Keywords:
Rivaroxaban;
Non-valvular atrial fibrillation;
Anticoagulation;
Clinical pharmacist;
Prescription intervention
- From:
Herald of Medicine
2025;44(11):1804-1807
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect of clinical pharmacists in prescription intervention on rivaroxaban anticoagulation within non-valvular atrial fibrillation(NVAF)patients.Methods We collected 101 NVAF patients from January to June 2022 as the control group,and 125 NVAF patients from January to June 2023 after clinical pharmacists intervention as observation group.We audited the rivaroxaban prescriptions of the two groups of patients according to the evaluation criterion of appropriateness of rivaroxaban prescriptions for NVAF patients in our hospital.The rationality of rivaroxaban prescriptions,rivaroxaban anticoagulation-related thrombotic events,and bleeding events were compared between two groups.Results Clinical pharmacists provided 105 prescription interventions for observation group patients,of which 69(65.7%)were adopted and implemented by doctors.The rational rate of rivaroxaban prescription in the observation group was significantly increased(85.7%vs.16.8%,P<0.05).There were no statistical differences between the observation group and the control group in thrombotic events and major bleeding events during hospitalization(P>0.05),with a significant difference in thrombotic events 6 months after discharged(0.8%vs.7.9%,P<0.05).Conclusion The clinical pharmacist prescription intervention can improve the rational rate of rivaroxaban prescription and reduce the risk of thrombotic and bleeding events,which is an important measure to advance the safety and effectiveness of anticoagulant therapy.
